The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of neoadjuvant bevacizumab at the time of surgery after 6 weeks of preoperative cessation: A translational study.
Patrick Starlinger
No relevant relationships to disclose
Lejla Alidzanovic
No relevant relationships to disclose
Dominic Schauer
No relevant relationships to disclose
Thomas Maier
No relevant relationships to disclose
Silvia Sommerfeldt
No relevant relationships to disclose
Beata Perisanidis
No relevant relationships to disclose
Dietmar Tamandl
No relevant relationships to disclose
Birgit Gruenberger
No relevant relationships to disclose
Thomas Gruenberger
No relevant relationships to disclose
Christine Brostjan
No relevant relationships to disclose